# A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Source: https://onco.cc/trials/nct05023980/  
OnCo record `nct05023980` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pirtobrutinib, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting.

## Summary

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) is a phase 3 interventional study registered as NCT05023980 by Loxo Oncology, Inc., with 309 participants enrolled, started 2021-09-23 and due to reach its primary completion in 2025-07-11. Interventions recorded: Pirtobrutinib, Bendamustine and Rituximab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05023980
- Phase: 3
- Setting: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Sponsor: Loxo Oncology, Inc.
- Enrolled: 309

## Sources

- ClinicalTrials.gov NCT05023980: https://clinicaltrials.gov/study/NCT05023980

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct05023980.json